Tesamorelin has more randomized human data behind it than almost any other peptide sold on the research market, but that data had never been formally pooled. A 2026 systematic review and meta-analysis in Obesity Research & Clinical Practice closed that gap, combining five randomized controlled trials of tesamorelin versus placebo and running the results through RoB 2.0 risk-of-bias assessment and GRADE certainty grading (PMID 41545261).
The headline numbers are consistent with what the individual Phase 3 trials reported. The more useful finding is the negative one: across five trials, tesamorelin produced no significant change in BMI and no significant reduction in subcutaneous fat. It moved the visceral compartment, the liver, and lean mass, and left the scale roughly where it started. That distinction explains a lot of the confusion in community discussion, where "it did nothing" and "my waist dropped two inches" are frequently the same result described two different ways.
Research-context information only. Tesamorelin is the active ingredient in an FDA-approved product for HIV-associated lipodystrophy only; off-label and research-peptide use is not FDA-approved. Protocols, doses, and reactions reported below come from published clinical trials and self-reported community sources. This article reports what has been documented, not what should be done. Possession or use of investigational drugs outside an authorized clinical trial may be illegal in your jurisdiction. Consult a licensed physician for personal medical decisions.
What the Analysis Pooled
The authors searched PubMed, Embase, Scopus, Web of Science, and CENTRAL through July 2025 for randomized controlled trials comparing tesamorelin against placebo in adults with HIV. Five RCTs met inclusion criteria. A random-effects model was applied across body composition, hepatic, metabolic, hormonal, and adverse-event outcomes.
Five trials is a small pool by cardiology or oncology standards. It is a large one for a peptide. Most compounds in this category — BPC-157, MOTS-c, epitalon — have zero completed placebo-controlled human trials to pool. Tesamorelin's evidence base is the reason it is one of a handful of peptides with an approved indication rather than a research-use-only label.
Visceral Fat: The Largest Documented Effect
The pooled estimate for visceral adipose tissue was a mean difference of -27.71 cm² versus placebo (95% CI -38.37 to -17.06; P < 0.001). Trunk fat fell by 1.18 kg (95% CI -1.40 to -0.96; P < 0.001) and waist circumference by 1.61 cm (95% CI -2.28 to -0.95; P < 0.001).
Two things are worth separating here. The pivotal Phase 3 trial published in the New England Journal of Medicine reported visceral fat reduction as a relative figure of roughly 15% at 26 weeks (PMID 18057338). The meta-analysis reports an absolute figure in square centimetres. The two are not interchangeable, and the absolute number will read as smaller or larger depending on the baseline visceral fat of the population it is applied to.
The confidence interval is also informative. The lower bound sits at -17.06 cm², meaning even the conservative end of the pooled estimate is a real reduction, not a null result dressed up by a favourable point estimate.
Liver Fat and the Hepatic Signal
Hepatic fat percentage dropped by 4.28 percentage points (95% CI -6.31 to -2.24; P < 0.001). This is the outcome that has driven most of the recent research interest in tesamorelin outside its approved indication, because visceral adiposity and hepatic steatosis travel together.
That signal was established before the meta-analysis. A 12-month randomized trial in Lancet HIV reported reduced liver fat and lower progression of fibrosis in participants with non-alcoholic fatty liver disease (PMID 31611038), and an earlier JAMA trial documented parallel visceral and liver fat reductions in participants with abdominal fat accumulation (PMID 25038357). The pooled estimate puts a confidence interval around what those trials individually observed.
Lean Body Mass Increased
Lean body mass rose by 1.42 kg (95% CI 1.13 to 1.71; P < 0.001). This is the outcome that separates a GHRH analogue from a caloric-restriction approach in the published record: the pooled trials documented fat compartment reduction alongside an increase in lean tissue rather than the loss that typically accompanies weight reduction.
The mechanism is not disputed. Tesamorelin stimulates endogenous growth hormone release, and the resulting IGF-1 elevation was documented across the pooled trials. The pooled Phase 3 dataset of 806 participants had already reported both the IGF-1 elevation and the lean-mass increase over 52 weeks (PMID 20554713); a separate analysis reported decreased muscle fat and increased muscle area (PMID 31237318).
What Did Not Move
This is the part of the analysis that most changes how the published record should be read.
| Outcome | Pooled result |
|---|---|
| Visceral adipose tissue | -27.71 cm² (P < 0.001) |
| Trunk fat | -1.18 kg (P < 0.001) |
| Hepatic fat | -4.28 percentage points (P < 0.001) |
| Waist circumference | -1.61 cm (P < 0.001) |
| Lean body mass | +1.42 kg (P < 0.001) |
| Limb fat | -0.22 kg (P = 0.001) |
| Subcutaneous adipose tissue | No significant change |
| BMI | No significant change |
| CD4+ T-cell count | No significant change |
Subcutaneous fat did not significantly change. Limb fat fell by 0.22 kg — statistically significant, practically negligible. BMI did not significantly change. Whatever tesamorelin did to the visceral compartment in these trials, it did not translate into a net reduction in body mass.
That is the honest framing of the compound in the published literature: it is documented as a visceral fat and hepatic fat agent that preserves or adds lean tissue. It is not documented as a weight-loss agent, and the pooled data does not support presenting it as one. Trial subjects who tracked outcomes by scale weight would have recorded a non-response; the same subjects tracked by waist circumference or imaging recorded a clear one.
Safety Outcomes in the Pooled Data
The reported adverse events were arthralgia, myalgia, paresthesia, and injection-site reactions including erythema. CD4+ T-cell counts showed no significant change across the pooled trials — a specific concern in an HIV population and the reason it was measured. The authors concluded that the pooled body composition, hepatic fat, lean mass, and IGF-1 effects occurred without serious side effects and without perturbation of glucose control.
Joint and limb symptoms and paresthesia are the expected fingerprint of GH-axis stimulation and appear consistently across the growth hormone secretagogue literature, not just tesamorelin's. The injection-site erythema entry is the one with practical relevance for anyone working from published protocols, since reconstitution technique, diluent quality, and storage all sit upstream of local site reactions.
